Sound Income Strategies’s Galectin Therapeutics GALT Stock Holding History

Sound Income Strategies’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,980	Closed	-$7.99K	–	1202
2026 Q1	$7.99K	Hold	2,980	–	–	﹤0.01%	1619
2025 Q4	$9.06K	Hold	2,980	–	–	﹤0.01%	1529
2025 Q3	$14.2K	Hold	2,980	–	–	﹤0.01%	908
2025 Q2	$6.29K	Hold	2,980	–	–	﹤0.01%	1036
2025 Q1	$3.64K	Hold	2,980	–	–	﹤0.01%	1128
2024 Q4	$3.84K	Hold	2,980	–	–	﹤0.01%	1045
2024 Q3	$8.2K	Hold	2,980	–	–	﹤0.01%	842
2024 Q2	$6.74K	Hold	2,980	–	–	﹤0.01%	867
2024 Q1	$7.12K	Hold	2,980	–	–	﹤0.01%	835
2023 Q4	$4.95K	Hold	2,980	–	–	﹤0.01%	897
2023 Q3	$5.72K	Hold	2,980	–	–	﹤0.01%	724
2023 Q2	$4.29K	Hold	2,980	–	–	﹤0.01%	766
2023 Q1	$6.26K	Buy	+2,980	New	+$4.81K	﹤0.01%	657

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Sound Income Strategies's GALT Position: Q2 2026 in Review

Sound Income Strategies sold out of Galectin Therapeutics (GALT) in Q2 2026, closing a stake of 2,980 shares — an estimated $7.99K sold.

Sound Income Strategies first reported a position in GALT in Q1 2023 and held it in 13 quarters. The position peaked at $14.2K in Q3 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

Sound Income Strategies reported no remaining Galectin Therapeutics position as of Q2 2026 after selling out during the quarter.
Sound Income Strategies sold 2,980 Galectin Therapeutics shares in Q2 2026, an estimated $7.99K.
Sound Income Strategies first reported a position in Galectin Therapeutics in Q1 2023 and held it in 13 quarters.
Sound Income Strategies's Galectin Therapeutics position peaked at $14.2K in Q3 2025.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Sound Income Strategies's 13F filing for Q2 2026, filed 20 Jul 2026.